European Journal of Internal Medicine
Volume 20, Issue 4 , Pages 369-372 , July 2009

Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment

  • Ibrahim Koral Onal

      Affiliations

    • Hacettepe University Medical School, Ankara, Turkey
    • Corresponding Author InformationCorresponding author. Türkiye Yüksek İhtisas Eğitim ve Araştırma Hastanesi, Gastroenteroloji Servisi-Sıhhiye, Ankara, PC:06100, Turkey. Tel.: +90 3123061334.
    • ,
  • Bulent Altun

      Affiliations

    • Department of Internal Medicine, Hacettepe University Medical School, Ankara, Turkey
    • ,
  • Eda Demir Onal

      Affiliations

    • Hacettepe University Medical School, Ankara, Turkey
    • ,
  • Alper Kırkpantur

      Affiliations

    • Department of Nephrology, Hacettepe University Medical School, Ankara, Turkey
    • ,
  • Serife Gul Oz

      Affiliations

    • Department of Internal Medicine, Hacettepe University Medical School, Ankara, Turkey
    • ,
  • Cetin Turgan

      Affiliations

    • Department of Internal Medicine, Hacettepe University Medical School, Ankara, Turkey

Received 4 April 2008 ,Revised 18 October 2008 ,Accepted 24 October 2008.

References 

  1. Chobanian AV, Bakris GL, Black HR, et al. National heart, lung, and blood institute Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure; national high blood pressure education program coordinating committee: The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 Report. JAMA. 2003;289:2560–2572
  2. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):1–266.
  3. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension. Hypertension. 2000;36:312–318
  4. Tayebjee MH, Nadar SK, MacFadyen RJ, Lip GY. Tissue inhibitor of MMP-1 and MMP-9 levels in patients with hypertension. Relationship to tissue Doppler indices of diastolic relaxation. AJH. 2004;17:770–774
  5. Schieffer B, Bunte C, Witte J, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol. 2004;44:362–368
  6. Tayebjee MH, Lim HS, Macfadyen RJ, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes. Effect of 1 years cardiovascular risk reduction therapy. Diabetes Care. 2004;27:2049–2051
  7. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol. 2000;75:43–47
  8. Li H, Simon H, Bocan TM, Peterson JT. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. Cardiovasc Res. 2000;46:298–306
  9. Bolbrinker J, Markovic S, Wehland M, Melenhorst WB, van Goor H, Kreutz R. Expression and response to ACE-inhibition of matrix metalloproteinases-2 and -9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension. J Pharmacol Exp Ther. 2006;316:8–16
  10. Asanuma K, Magid R, Johnson C, Nerem RM, Galis ZS. Uniaxial strain upregulates matrix-degrading enzymes produced by human vascular smooth muscle cells. Am J Physiol. 2003;284:1778–1784
  11. O Callaghan JC, Williams B. Mechanical strain-induced extracellular matrix production by human vascular smooth muscle cells: role of TGF-β1. Hypertension. 2000;36:319–324
  12. Donnelly R, Collinson DJ, Manning G. Hypertension, matrix metalloproteinases and target organ damage. J Hypertens. 2003;21:1627–1630
  13. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Am J Pathol. 1996;148:1639–1648
  14. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross links. Am J Pathol. 1996;148:1345–1350.
  15. Eddy AA, Kim H, Lopez-Guisa J, Oda T, Soloway PD. Interstitial fibrosis in mice with overload proteinuria: deficiency of TIMP-1 is not protective. Kidney Int. 2000;58:618–628
  16. Li X, Meng Y, Yang XS, Mi LF, Cai SX. ACEI attenuates the progression of CCl4- induced rat hepatic fibrogenesis by inhibiting TGF-beta1, PDGF-BB, NF-kappaB and MMP- 2,9. World J Gastroenterol. 2005;11:4807–4811
  17. Williams RN, Parsons SL, Morris TM, Rowlands BJ, Watsons SA. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol. 2005;31:1042–1050
  18. Jesmin S, Sakuma I, Hattori Y, Kitabatake A. Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulin-resistant diabetic rats. Arterioscler Thromb Vasc Biol. 2003;23:2021–2026
  19. Gurjar MV, Sharma RV, Bhalla RC. eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arterioscler Thromb Vasc Bio. 1999;19:2871–2877
  20. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995;77:863–868
  21. Laviades C, Varo N, Fernández J, Mayor G, Gil MJ, Monreal I, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation. 1998;98:535–540
  22. Ergul A, Dobos VP, Hutchinson J, Franco J, Anstadt MP. Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients. AJH. 2004;17:775–782
  23. Liebetrau M, Burggrafb D, Wunderlichb N, Jager G, Linz W, Hamann GF. ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats. Neuroscience Letters. 2005;376:205–209
  24. Yasmin , Mc Eniery CM, Wallace S, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25:372
  25. Zervoudaki A, Economou E, Pitsavos C, et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens. 2003;17:119–124
  26. Verdecchia P, Reboldi GP. Hypertension and microalbuminuria: the new detrimental duo. Blood Pres. 2004;13:198–211
  27. Ebihara I, Nakamura T, Shimada N, Koide H. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis. 1998;32:544–550

☆ Supported by: LUT 04/61, Turkish Hypertension and Kidney Disease Foundation, Astra Zeneca.

PII: S0953-6205(08)00296-3

doi: 10.1016/j.ejim.2008.10.003

European Journal of Internal Medicine
Volume 20, Issue 4 , Pages 369-372 , July 2009

Article Tools